Press Releases
Filter By Year
October
-
October 21, 2021
Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV -
October 19, 2021
Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia -
October 18, 2021
U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations -
October 15, 2021
Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer -
October 14, 2021
Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021 -
October 01, 2021
U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
September
-
September 30, 2021
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma -
September 27, 2021
Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization -
September 22, 2021
Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19 -
September 20, 2021
Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021 -
September 16, 2021
New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status -
September 16, 2021
Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study -
September 13, 2021
Gilead to Present New Data at ESMO Congress 2021 Reinforcing the Practice-changing Potential of Trodelvy -
September 01, 2021
Gilead Sciences to Present at Upcoming Investor Conference
August
-
August 19, 2021
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options -
August 05, 2021
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer -
August 04, 2021
BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland -
August 03, 2021
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program
July
-
July 29, 2021
Gilead Sciences Announces Second Quarter 2021 Financial Results -
July 19, 2021
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD -
July 17, 2021
Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults -
July 17, 2021
New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor -
July 15, 2021
Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021 -
July 12, 2021
Gilead to Present New Data at IAS 2021 Demonstrating the Company’s Commitment to Advancing Innovation in HIV Research
June
-
June 28, 2021
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options -
June 28, 2021
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma -
June 24, 2021
Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks -
June 23, 2021
Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China -
June 21, 2021
Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets -
June 21, 2021
Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021 -
June 17, 2021
Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies -
June 12, 2021
Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis -
June 10, 2021
U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C -
June 04, 2021
Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation -
June 04, 2021
Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
May
April
-
April 29, 2021
Gilead Sciences Announces Second Quarter 2021 Dividend -
April 29, 2021
Gilead Sciences Announces First Quarter 2021 Financial Results -
April 26, 2021
Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India -
April 15, 2021
Gilead Sciences to Release First Quarter 2021 Financial Results on Thursday, April 29, 2021 -
April 13, 2021
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer -
April 07, 2021
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival -
April 01, 2021
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
March
-
March 31, 2021
Gilead Sciences Comments on the Passing of John C. Martin, PhD -
March 26, 2021
Gilead Sciences Appoints Flavius Martin, MD as Executive Vice President, Research -
March 25, 2021
European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer -
March 18, 2021
Gilead and Novo Nordisk Expand NASH Clinical Collaboration -
March 15, 2021
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV -
March 09, 2021
Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI -
March 06, 2021
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI -
March 05, 2021
U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy -
March 04, 2021
Gilead Sciences Completes Acquisition of MYR GmbH -
March 02, 2021
Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health Needs
February
-
February 18, 2021
Gilead Sciences to Present at Upcoming Investor Conferences -
February 16, 2021
Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach -
February 10, 2021
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma -
February 10, 2021
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF -
February 08, 2021
Kite Appoints Frank Neumann as Worldwide Head of Clinical Development -
February 04, 2021
Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend -
February 04, 2021
Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results -
February 02, 2021
Gilead and the Human Rights Campaign Will Work Together to Combat HIV Epidemic and Promote Transgender Justice -
February 01, 2021
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
January
-
January 21, 2021
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021 -
January 19, 2021
Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research -
January 12, 2021
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus -
January 11, 2021
Gilead Sciences Announces Updated 2020 Guidance -
January 06, 2021
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
Filter By Year